Targeting the TWEAK/Fn14 signalling pathway as a novel therapeutic strategy to prevent chronic liver disease progression.

靶向 TWEAK/Fn14 信号通路作为预防慢性肝病进展的新型治疗策略。

• 批准号: nhmrc : GNT1160323
• 金额: $ 99.75万
• 依托单位: Curtin University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-tweakfn14-signalling-disease-progression/1379121
• 关键词: Targeting; TWEAK; Fn14; signalling; pathway

TWEAK/Fn14 signalling critically regulates inflammation, fibrosis and liver progenitor cell responses - all processes involved in progressive chronic liver injury. In this study, we will now define the involved cell populations, identify the underlying mechanisms and test pharmacological targeting of this pathway as a novel therapeutic avenue to inhibit chronic liver disease progression to cancer. Importantly, we will also assess translatability of our findings into the human setting.

Tweak/FN14信号对炎症，纤维化和肝脏祖细胞反应进行严格调节 - 进行性慢性肝损伤所涉及的所有过程。在这项研究中，我们现在将定义所涉及的细胞群体，确定该途径的潜在机制和测试药理靶向，作为抑制慢性肝病进展到癌症的新型治疗途径。重要的是，我们还将评估发现结果向人类环境的转换性。